Changchun Hi-Tech announced that the holding subsidiary Jinsai Pharmaceutical's domestically produced drug registration clinical trial application for injectable GenSci 136 was accepted by the State Drug Administration. GenSci136 for injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is intended to be used to treat immunoglobulin A nephropathy. As a B-cell mature antigen trimer fusion protein, the drug can bind B-lymphocyte stimulating factors and proliferation-inducing ligands to block the interaction between BLiS and April and B-cell membrane receptors, and has the potential to treat humoral immune disorders and various autoimmune diseases where pathogenic antibodies are the core mechanism causing tissue damage.

Changchun Hi-Tech announced that the holding subsidiary Jinsai Pharmaceutical's domestically produced drug registration clinical trial application for injectable GenSci 136 was accepted by the State Drug Administration. GenSci136 for injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is intended to be used to treat immunoglobulin A nephropathy. As a B-cell mature antigen trimer fusion protein, the drug can bind B-lymphocyte stimulating factors and proliferation-inducing ligands to block the interaction between BLiS and April and B-cell membrane receptors, and has the potential to treat humoral immune disorders and various autoimmune diseases where pathogenic antibodies are the core mechanism causing tissue damage.